234. Safety and Immunogenicity of mRNA-1345, an mRNA-Based RSV Vaccine in Younger and Older Adult Cohorts: Results from a Phase 1, Randomized Clinical Trial

BACKGROUND: Respiratory syncytial virus (RSV) is a public health burden; no vaccine is currently available. An mRNA-based RSV vaccine (mRNA-1345) encoding the RSV prefusion stabilized F (preF) glycoprotein is under clinical investigation. METHODS: A phase 1, randomized, observer-blind, placebo-contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Grace L, Mithani, Runa, Kapoor, Archana, Lu, Sophia, Asmar, Laila El, Panozzo, Catherine A, Shaw, Christine A, Stoszek, Sonia K, August, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752082/
http://dx.doi.org/10.1093/ofid/ofac492.312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752082/
http://dx.doi.org/10.1093/ofid/ofac492.312

Ejemplares similares